Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art

Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs with potent hypoglycemic effects. Recent evidence suggests that these drugs have extraglycemic impacts and are therefore able to provide additional benefits beyond glucose lowering. Mitochondrial dysfunction is a central facet of many disorders that negatively impacts many tissues and organs, especially in the setting of diabetes. Therefore, it would be hugely beneficial if an antidiabetic drug could also provide mitochondrial benefits to improve cellular function and reduce the risk of diabetic complications. In this review, we have surveyed the literature for possible mitochondrial benefits of SGLT2is and we discuss the possible mechanisms involved.
Original languageEnglish
Pages (from-to)53-66
Number of pages14
JournalEXCLI Journal
Publication statusPublished - 2 Jan 2023


Dive into the research topics of 'Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art'. Together they form a unique fingerprint.

Cite this